Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for ImageneBio, Inc. (IMA : NSDQ)

• Company Description    Inmagene Biopharmaceuticals is a clinical stage biotechnology company dedicated to developing disease-modifying treatments for immunological/autoimmune and inflammatory diseases. The company's lead asset includes IMG-007, a nondepleting anti-OX40 monoclonal antibody. Inmagene Biopharmaceuticals, formerly known as Ikena Oncology Inc., is based in SAN DIEGO. Number of Employees: 10

• Price / Volume Information    Yesterday's Closing Price: $8.29 Daily Weekly Monthly 20 Day Moving Average: 66,916 shares Shares Outstanding: 4.01 (millions) Market Capitalization: $33.21 (millions) Beta: 0.42 52 Week High: $18.00 52 Week Low: $5.82 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week 4.15% 1.42% 12 Week -41.62% -44.04% Year To Date -57.89% -63.19%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 645 SUMMER STREET SUITE 101 - BOSTON,MA 02210 USA ph: 857-273-8343 fax: - info@ikenaoncology.com http://www.ikenaoncology.com

• General Corporate Information    Officers Mark Manfredi - President; Chief Executive Officer and Director Jotin Marango - Chief Financial Officer; Chief Operating Officer Owen Hughes - Director David Bonita - Director Iain D. Dukes - Director Peer Information ImageneBio, Inc. (CORR.) ImageneBio, Inc. (RSPI) ImageneBio, Inc. (CGXP) ImageneBio, Inc. (BGEN) ImageneBio, Inc. (GTBP) ImageneBio, Inc. (RGRX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 45175G207 SIC: 2836 Fiscal Year Fiscal Year End: December Last Reported Quarter: 06/01/25 Next Expected EPS Date: 11/06/25 Share - Related Items Shares Outstanding: 4.01 Most Recent Split Date: 7.00 (0.08:1) Beta: 0.42 Market Capitalization: $33.21 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-1.38 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-5.70 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 2.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 11/06/25

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 0.29 Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: 77.78% vs. Previous Quarter: 66.67% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -% ROE 09/30/25 - - 06/30/25 - -23.94 03/31/25 - -30.59 ROA 09/30/25 - - 06/30/25 - -21.62 03/31/25 - -27.55 Current Ratio 09/30/25 - - 06/30/25 - 13.52 03/31/25 - 13.31 Quick Ratio 09/30/25 - - 06/30/25 - 13.52 03/31/25 - 13.31 Operating Margin 09/30/25 - - 06/30/25 - - 03/31/25 - - Net Margin 09/30/25 - - 06/30/25 - - 03/31/25 - - Pre-Tax Margin 09/30/25 - - 06/30/25 - - 03/31/25 - - Book Value 09/30/25 - - 06/30/25 - 28.94 03/31/25 - 29.42 Inventory Turnover 09/30/25 - - 06/30/25 - - 03/31/25 - - Debt-to-Equity 09/30/25 - - 06/30/25 - 0.00 03/31/25 - 0.00 Debt-to-Capital 09/30/25 - - 06/30/25 - 0.00 03/31/25 - 0.00

Powered by Zacks Investment Research ©